Clinical trials: Neoepitopes
The Initial Aim of This Project is to Perform in Vitro Validation of Neoepitope Candidates Selected From Available Mutanome Data
Identification of Immunogenic Neo-epitopes for the Development of Personalised Pancreatic Cancer Vaccines
Human pancreatic cancer has a very poor prognosis with an overall survival rate of less than 5%. Current treatment regimens are ineffective and even if the patient responds to initial treatments, relapse is common due to the…
- Trial name
- CanVac (NCT04379960)
- Testing
- Peptides
- Where
- United Kingdom
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Queen Mary University of London